Regenxbio (RGNX) Lowered to “Hold” at ValuEngine

Regenxbio (NASDAQ:RGNX) was downgraded by investment analysts at ValuEngine from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.

Other equities analysts have also recently issued reports about the stock. Raymond James set a $96.00 price objective on shares of Regenxbio and gave the company a “buy” rating in a research note on Thursday, November 8th. Zacks Investment Research raised shares of Regenxbio from a “hold” rating to a “buy” rating and set a $78.00 price objective on the stock in a research note on Wednesday, November 7th. BidaskClub raised shares of Regenxbio from a “hold” rating to a “buy” rating in a research note on Saturday, November 3rd. Chardan Capital reduced their price objective on shares of Regenxbio from $130.00 to $127.50 and set a “buy” rating on the stock in a research note on Wednesday, August 8th. Finally, TheStreet raised shares of Regenxbio from a “d+” rating to a “c” rating in a research note on Monday, September 17th. One analyst has rated the stock with a sell rating, five have issued a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $77.81.

RGNX opened at $54.56 on Wednesday. Regenxbio has a one year low of $23.25 and a one year high of $85.10. The company has a market cap of $2.15 billion, a PE ratio of -22.27, a P/E/G ratio of 8.84 and a beta of -0.52.

Regenxbio (NASDAQ:RGNX) last released its quarterly earnings results on Wednesday, November 7th. The biotechnology company reported ($0.56) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.86) by $0.30. Regenxbio had a net margin of 44.30% and a return on equity of 22.52%. The business had revenue of $5.31 million for the quarter. On average, analysts anticipate that Regenxbio will post 2.23 EPS for the current fiscal year.

In other Regenxbio news, CEO Kenneth T. Mills sold 7,510 shares of the stock in a transaction on Monday, October 15th. The shares were sold at an average price of $59.35, for a total value of $445,718.50. Following the sale, the chief executive officer now directly owns 331,710 shares in the company, valued at $19,686,988.50. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Luke M. Beshar sold 12,784 shares of the stock in a transaction on Thursday, November 29th. The stock was sold at an average price of $65.00, for a total transaction of $830,960.00. Following the completion of the sale, the director now owns 12,784 shares in the company, valued at $830,960. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 448,954 shares of company stock worth $28,902,916. Insiders own 16.90% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the business. Marshall Wace LLP acquired a new stake in Regenxbio in the second quarter worth $14,712,000. RTW Investments LP raised its holdings in Regenxbio by 10.7% in the second quarter. RTW Investments LP now owns 2,079,555 shares of the biotechnology company’s stock worth $149,208,000 after purchasing an additional 201,788 shares during the period. Chicago Equity Partners LLC acquired a new stake in Regenxbio in the second quarter worth $3,195,000. Northern Trust Corp raised its holdings in Regenxbio by 21.2% in the second quarter. Northern Trust Corp now owns 359,040 shares of the biotechnology company’s stock worth $25,762,000 after purchasing an additional 62,849 shares during the period. Finally, Strs Ohio raised its holdings in Regenxbio by 32.4% in the second quarter. Strs Ohio now owns 18,800 shares of the biotechnology company’s stock worth $1,348,000 after purchasing an additional 4,600 shares during the period. Institutional investors own 79.08% of the company’s stock.

About Regenxbio

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.

Recommended Story: Earnings Reports

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Regenxbio (NASDAQ:RGNX)

Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit